Publications by authors named "Kevin B Kim"

100Publications

Complete clinical response to intralesional talimogene laherparepvec injection in a patient with recurrent, regionally advanced Merkel cell carcinoma.

JAAD Case Rep 2019 Oct 24;5(10):849-851. Epub 2019 Sep 24.

Center for Melanoma Research and Treatment, California Pacific Medical Center Research Institute, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2019.07.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804468PMC
October 2019

Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective study.

Cancer Epidemiol 2018 12 19;57:80-84. Epub 2018 Oct 19.

The University of Texas MD Anderson Cancer Center, Houston, TX, USA; California Pacific Medical Center Research Institute, San Francisco, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18777821183041
Publisher Site
http://dx.doi.org/10.1016/j.canep.2018.10.003DOI Listing
December 2018

Case Report of a Pregnancy During Ipilimumab Therapy.

J Glob Oncol 2018 09 22;4:1-3. Epub 2017 Aug 22.

All authors: California Pacific Medical Center, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JGO.17.00019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180753PMC
September 2018

Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs.

Clin Exp Metastasis 2018 08 17;35(5-6):503-520. Epub 2018 Jul 17.

California Pacific Medical Center Research Institute, 2333 Buchanan St., San Francisco, CA, 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10585-018-9913-yDOI Listing
August 2018

Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies.

BMC Cancer 2018 04 27;18(1):490. Epub 2018 Apr 27.

Center for Melanoma Research and Treatment, California Pacific Medical Center Research Institute, 2100 Webster Street, Suite 326, San Francisco, CA, 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-018-4374-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924486PMC
April 2018

Diffuse granulomatous panniculitis associated with anti PD-1 antibody therapy.

JAAD Case Rep 2018 Jan 18;4(1):13-16. Epub 2017 Dec 18.

California Pacific Medical Center, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2017.06.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739149PMC
January 2018

A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.

Cancer Immunol Immunother 2017 Oct 13;66(10):1359-1366. Epub 2017 Jun 13.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-017-2030-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898971PMC
October 2017

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

J Clin Oncol 2016 Mar 25;34(8):871-8. Epub 2016 Jan 25.

Georgina V. Long, Melanoma Institute Australia; The University of Sydney; Richard F. Kefford, Melanoma Institute Australia; The University of Sydney; Macquarie University, Sydney; Westmead Hospital, Westmead; Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia; Jeffrey S. Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute/Tennessee Oncology; Kevin B. Kim, California Pacific Medical Center; Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, Karl Lewis, University of Colorado; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Jeffrey A. Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Elizabeth Cunningham, Merck; Peng Sun, Amy S. Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia, PA; Donald Lawrence and Kiran Patel, Incyte Corporation, Wilmington, DE; and Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.62.9345
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.62.9345DOI Listing
March 2016

Intratumoral talimogene laherparepvec therapy in melanoma.

Authors:
Kevin B Kim

Melanoma Manag 2015 Nov 19;2(4):297-300. Epub 2015 Nov 19.

California Pacific Medical Center, 2333 Buchanan St., San Francisco, CA 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt.15.28DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094683PMC
November 2015

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.

Eur J Cancer 2015 Nov 10;51(17):2689-97. Epub 2015 Sep 10.

Department of Medicine, Division of Hematology/Oncology, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.08.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821004PMC
November 2015

Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report.

BMC Cancer 2015 May 13;15:400. Epub 2015 May 13.

California Pacific Medical Center for Melanoma Research and Treatment, San Francisco Oncology Associates, 2333 Buchanan St., San Francisco, CA, 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-1391-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440312PMC
May 2015

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.

BMC Cancer 2015 Feb 18;15:61. Epub 2015 Feb 18.

Center for Personalized Cancer Therapy, Moores Cancer Center, The University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA, 92093, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-1029-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340232PMC
February 2015

Treatment of KIT-mutated metastatic mucosal melanoma.

Chin Clin Oncol 2014 Sep;3(3):35

Department of Internal Medicine, Section of Hematology/Oncology, University of Oklahoma, Oklahoma City, OK 73104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2304-3865.2014.08.02DOI Listing
September 2014

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

J Clin Oncol 2014 Nov 6;32(33):3697-704. Epub 2014 Oct 6.

Douglas B. Johnson and Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Keith T. Flaherty and Donald P. Lawrence, Massachusetts General Hospital Cancer Center, Boston MA; Jeffrey S. Weber and Geoffrey T. Gibney, Moffitt Cancer Center, Tampa, FL; Kevin B. Kim and Gerald S. Falchook, University of Texas MD Anderson Cancer Center, Houston, TX; Richard F. Kefford and Georgina V. Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales; Jonathan Cebon, Joint Ludwig-Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia; Omid Hamid, Angeles Clinic and Research Institute, Los Angeles; Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA; William H. Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Robert R. McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Karl Lewis and Rene Gonzalez, University of Colorado, Denver, CO; and Kiran Patel, Incyte, Wilmington, DE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.3535DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226803PMC
November 2014

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.

J Clin Oncol 2014 Nov 29;32(32):3659-66. Epub 2014 Sep 29.

Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.54.8115
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.54.8115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879709PMC
November 2014

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).

Clin Cancer Res 2014 Sep 23;20(17):4449-58. Epub 2014 Jun 23.

Melanoma Institute Australia and University of Sydney, New South Wales, Australia. Westmead Institute for Cancer Research, Westmead Millennium Institute, and Department of Medical Oncology, Westmead Hospital, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-14-0887DOI Listing
September 2014

Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapy.

Am J Dermatopathol 2014 Jul;36(7):557-61

Departments of *Pathology, †Dermatology, and ‡Atlanta Dermatopathology, Atlanta, GA; and §Melanoma Medical Oncology, and ¶Investigative Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000000018DOI Listing
July 2014

Dabrafenib.

Recent Results Cancer Res 2014 ;201:227-40

Department of Internal Medicine, Baylor College of Medicine, Houston, TX, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-642-54490-3_14DOI Listing
September 2014

Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma.

Melanoma Res 2014 Aug;24(4):342-8

aHealth Science Center, University of Oklahoma, Oklahoma City, Oklahoma Departments of bMelanoma Medical Oncology cPalliative Care and Rehabilitative Medicine dBiostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278368PMC
August 2014

Dabrafenib for the treatment of melanoma.

Expert Opin Pharmacother 2014 May 10;15(7):1043-50. Epub 2014 Apr 10.

The University of Texas MD Anderson Cancer Center, Department of Melanoma Medical Oncology , Unit 430, 1515 Holcombe Blvd, Houston, TX 77030 , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2014.909410DOI Listing
May 2014

Case of vemurafenib-induced Sweet's syndrome.

J Dermatol 2014 Sep 12;41(9):817-20. Epub 2014 Mar 12.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.12430DOI Listing
September 2014

Dabrafenib for treatment of BRAF-mutant melanoma.

Pharmgenomics Pers Med 2014 31;7:21-9. Epub 2013 Dec 31.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/PGPM.S37220DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917541PMC
June 2014

PFS as a surrogate for overall survival in metastatic melanoma.

Authors:
Kevin B Kim

Lancet Oncol 2014 Mar 31;15(3):246-8. Epub 2014 Jan 31.

University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(14)70039-7DOI Listing
March 2014

Dabrafenib therapy for advanced melanoma.

Ann Pharmacother 2014 Apr 20;48(4):519-29. Epub 2013 Nov 20.

University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028013513009DOI Listing
April 2014

MEK inhibition in the treatment of advanced melanoma.

Curr Oncol Rep 2013 Oct;15(5):473-82

Division of Medical Oncology, Duke University Medical Center, DUMC 3476, Durham, NC, 27710, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-013-0336-2DOI Listing
October 2013

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma.

Cancer 2013 Nov 6;119(21):3821-9. Epub 2013 Aug 6.

Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28306DOI Listing
November 2013

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.

J Clin Oncol 2013 Sep 5;31(26):3205-11. Epub 2013 Aug 5.

Paolo A. Ascierto, Ester Simeone, Instituto Nazionale Tumori Fondazione "G. Pascale," Napoli, Italy; David Minor, California Pacific Center for Melanoma Research and Treatment, San Francisco; Antoni Ribas, Jonsson Comprehensive Cancer Center, University of California, Los Angeles; Omid Hamid, Experimental Therapeutics/Immunotherapy, The Angeles Clinic and Research Institute, Los Angeles, CA; Anne O'Hagan, Niki Arya, Mary Guckert, Anne-Marie Martin, Jolly Mazumdar, Vicki L. Goodman, GlaxoSmithKline Oncology, Collegeville; Ravi Amaravadi, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Kevin B. Kim, The University of Texas MD Anderson Cancer Center, Houston, TX; Celeste Lebbe, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Paris, Université Paris Diderot, Paris; Jean-Jacques Grob, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Hôpital Timone, Marseille, France; Dirk Schadendorf, University Hospital Essen, Essen; Tabea Wilhelm, Uwe Trefzer, Charité-Universitätsmedizin, Berlin, Germany; Richard F. Kefford, Georgina V. Long, Westmead Hospital and Melanoma Institute Australia, University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.49.8691
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.49.8691DOI Listing
September 2013

Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions.

Int J Dermatol 2014 Mar 24;53(3):376-84. Epub 2013 Jul 24.

Department of Pathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA; Department of Dermatology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.12205DOI Listing
March 2014

Immunohistochemical expression of hormone receptors in melanoma of pregnant women, nonpregnant women, and men.

Am J Dermatopathol 2014 Jan;36(1):74-9

Departments of *Pathology, †Melanoma Medical Oncology, ‡Head and Neck Surgery, and §Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0b013e3182914c64DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795893PMC
January 2014

Drug safety evaluation of vemurafenib in the treatment of melanoma.

Expert Opin Drug Saf 2013 Sep 26;12(5):767-75. Epub 2013 Jun 26.

The University of Texas MD Anderson Cancer Center, Dermatology, 1515 Holcombe Blvd, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14740338.2013.813017DOI Listing
September 2013

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

J Clin Oncol 2013 Sep 17;31(26):3182-90. Epub 2013 Jun 17.

F. Stephen Hodi, Anita Giobbie-Hurder, Philip Friedlander, Jason J. Luke, Katherine A. Zukotynski, Jeffrey T. Yap, Annick D. Van den Abbeele, and George D. Demetri, Dana-Farber Cancer Institute; Jonathan A. Fletcher, Meijun Zhu, and Adrian Marino-Enriquez, Brigham and Women's Hospital; Donald Lawrence, Keith T. Flaherty, and David E. Fisher, Massachusetts General Hospital, Boston, MA; Christopher L. Corless, Michael C. Heinrich, and Carol Beadling, Portland Veterans Administration Medical Center and Oregon Health & Science University, Portland, OR; Philip Friedlander, Mount Sinai Medical Center, New York, NY; Rene Gonzalez, University of Colorado Cancer Center, Aurora, CO; Jeffrey S. Weber, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Thomas F. Gajewski, University of Chicago, Chicago, IL; Steven J. O'Day, Beverly Hills Cancer Center, Beverly Hills, CA; Kevin B. Kim, The University of Texas MD Anderson Cancer Center, Houston, TX; Frances A. Collichio, The University of North Carolina at Chapel Hill, Chapel Hill, NC; and Marc S. Ernstoff, Geisel School of Medicine and Norris Cotton Cancer Center, Hanover, NH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.7836DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878082PMC
September 2013

The past, present, and future of melanoma therapy.

Authors:
Kevin B Kim

Oncology (Williston Park) 2013 May;27(5):391-3

View Article

Download full-text PDF

Source
May 2013

Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.

Thyroid 2013 Oct 17;23(10):1277-83. Epub 2013 Jul 17.

1 Department of Melanoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center , Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/thy.2013.0057DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967415PMC
October 2013

Trametinib (GSK1120212) in the treatment of melanoma.

Expert Opin Pharmacother 2013 Apr 23;14(5):619-27. Epub 2013 Feb 23.

Duke University Medical Center, Division of Medical Oncology, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2013.770475DOI Listing
April 2013

Arginine deprivation therapy for malignant melanoma.

Clin Pharmacol 2013 27;5:11-9. Epub 2012 Dec 27.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA ; Hwasung Public Health Center, Hwasung, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CPAA.S37350DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534294PMC
January 2013

Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.

Cancer 2013 Feb 12;119(4):799-805. Epub 2012 Sep 12.

Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.27790DOI Listing
February 2013

BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma.

J Cutan Pathol 2012 Sep 19;39(9):821-5. Epub 2012 Jul 19.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-0560.2012.01950.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3881367PMC
September 2012

A lupus-like reaction to subcutaneous interferon-α at injection sites.

J Drugs Dermatol 2012 Mar;11(3):393-8

The University of Texas-Houston Medical School, Houston, TX, USA.

View Article

Download full-text PDF

Source
March 2012

Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.

Expert Opin Investig Drugs 2012 Apr 7;21(4):531-9. Epub 2012 Mar 7.

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2012.665871DOI Listing
April 2012

Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.

Clin Cancer Res 2012 Feb 5;18(4):1120-8. Epub 2012 Jan 5.

Departments of Melanoma Medical Oncology, Systems Biology, Biostatistics, Pathology, Experimental Therapeutics, and Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-2436DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906678PMC
February 2012

NRAS mutation status is an independent prognostic factor in metastatic melanoma.

Cancer 2012 Aug 16;118(16):4014-23. Epub 2011 Dec 16.

Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.26724DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3310961PMC
August 2012

Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma.

Clin Cancer Res 2011 Dec 5;17(23):7451-61. Epub 2011 Oct 5.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-11-1747DOI Listing
December 2011

Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neck.

Melanoma Res 2011 Apr;21(2):127-30

Department of Melanoma/Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0b013e3283426821DOI Listing
April 2011

Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function.

J Clin Pharmacol 2011 Aug 26;51(8):1205-12. Epub 2010 Oct 26.

Department of Melanoma Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1177/0091270010381499
Publisher Site
http://dx.doi.org/10.1177/0091270010381499DOI Listing
August 2011

Prognostic factors for survival in melanoma patients with brain metastases.

Cancer 2011 Apr 19;117(8):1687-96. Epub 2010 Oct 19.

Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77054, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25634DOI Listing
April 2011

Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma.

Melanoma Res 2010 Dec;20(6):507-10

Department of Melanoma Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0b013e3283403ce9DOI Listing
December 2010

Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy.

Melanoma Res 2010 Dec;20(6):501-6

Department of Melanoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00008390-201012000-000
Publisher Site
http://dx.doi.org/10.1097/CMR.0b013e32833faf18DOI Listing
December 2010

The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma.

Melanoma Res 2010 Feb;20(1):43-7

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0b013e3283324e2eDOI Listing
February 2010

Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients.

Melanoma Res 2009 Aug;19(4):238-42

Department of Melanoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, 1515 Holcombe Building, Unit 430, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0b013e32832a1e2fDOI Listing
August 2009

Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.

Am J Clin Oncol 2009 Oct;32(5):509-14

Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0b013e3181942a1fDOI Listing
October 2009

A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma.

Cancer Invest 2009 Aug;27(7):756-63

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/07357900802709159DOI Listing
August 2009

A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma.

Melanoma Res 2008 Dec;18(6):400-4

Department of Melanoma Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/melanomaresearch/2008/12000/A_p
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/CMR.0b013e328311aaa1DOI Listing
December 2008

Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma.

Cancer Chemother Pharmacol 2009 Jun 11;64(1):161-7. Epub 2008 Nov 11.

Department of Melanoma Medical Oncology, Unit 430, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-008-0861-0DOI Listing
June 2009

Biochemotherapy in patients with advanced head and neck mucosal melanoma.

Head Neck 2008 Dec;30(12):1592-8

The University of Texas Medical School at Houston, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hed.20910DOI Listing
December 2008

Use of sargramostim as maintenance therapy in patients with stage IV melanoma at high risk for systemic recurrence.

Melanoma Res 2007 Aug;17(4):257-9

MS IV, Florida State University College of Medicine, Tallahassee, Florida, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0b013e3282c3a71aDOI Listing
August 2007

Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).

J Cutan Pathol 2006 Apr;33(4):280-5

Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.0303-6987.2006.00432.xDOI Listing
April 2006

A phase II trial of arsenic trioxide in patients with metastatic melanoma.

Cancer 2005 Oct;104(8):1687-92

Department of Melanoma Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.21386DOI Listing
October 2005